NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified and
transduced with a lentiviral vector expressing a second-generation chimeric antigen
receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19,
with immunostimulating and antineoplastic activities. Upon administration, obecabtagene
autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic
T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis.
CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed
in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz
CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence
of the CAR T-cells.;